Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H28O8 |
| Molecular Weight | 384.4208 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4
InChI
InChIKey=FIHJKUPKCHIPAT-NKHDUEHSSA-N
InChI=1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16+,17-,18-,19-/m1/s1
| Molecular Formula | C19H28O8 |
| Molecular Weight | 384.4208 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.google.com/patents/WO2003048167A1Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26615886 | https://www.google.com/patents/WO2013177420A3
Sources: https://www.google.com/patents/WO2003048167A1
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26615886 | https://www.google.com/patents/WO2013177420A3
.BETA.-ARTESUNATE is enantiomer of artesunate -- a medication used to treat malaria. β-ARTESUNATE is a prodrug that is rapidly converted to its active form dihydroartemisinin. This process involves hydrolysis of the 4-carbon ester group via plasma esterase enzyme. It is hypothesized that the cleavage of endoperoxide bridge in the pharmacophore of DHA generates reactive oxygen species (ROS), which increases oxidative stress and causes malarial protein damage via alkylation. .BETA.-ARTESUNATE have potential application as anticancer agent.
Originator
Approval Year
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26615886
The in vitro cytotoxic activity of the compound 1 (BETA.-ARTESUNATE) was evaluated against sensitive human cancer cells (human hepatoma HepG2 cells, human lung adenocarcinoma A549 cells, human cervical carcinoma HeLa cells and human leukemic K562 cells), multidrug-resistant K562/ADR leukemia cells and human umbilical vein endothelial cells (HUVEC) by CCK-8 assay (drug exposure was for 72 h).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:33:26 GMT 2025
by
admin
on
Mon Mar 31 23:33:26 GMT 2025
|
| Record UNII |
USD5X0Z99I
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
759817
Created by
admin on Mon Mar 31 23:33:26 GMT 2025 , Edited by admin on Mon Mar 31 23:33:26 GMT 2025
|
PRIMARY | |||
|
182824-33-5
Created by
admin on Mon Mar 31 23:33:26 GMT 2025 , Edited by admin on Mon Mar 31 23:33:26 GMT 2025
|
PRIMARY | |||
|
DTXSID30861106
Created by
admin on Mon Mar 31 23:33:26 GMT 2025 , Edited by admin on Mon Mar 31 23:33:26 GMT 2025
|
PRIMARY | |||
|
USD5X0Z99I
Created by
admin on Mon Mar 31 23:33:26 GMT 2025 , Edited by admin on Mon Mar 31 23:33:26 GMT 2025
|
PRIMARY | |||
|
65664
Created by
admin on Mon Mar 31 23:33:26 GMT 2025 , Edited by admin on Mon Mar 31 23:33:26 GMT 2025
|
PRIMARY |